Plant Name: Melia indica
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| PDE5A; | |
| ALPI; MIF; AKR1B1; USP2; POLB; | |
| GAA; | |
| MAPK1; MAPK14; MAPK3; LCK; FYN; | |
| CA2; CA12; CA7; CA4; | |
| HMGCR; | |
| SLCO1B3; SLCO1B1; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Oxidoreductase | HMGCR | HMG-CoA reductase | P04035 | CHEMBL402 |
| Phosphodiesterase 5 | PDE5A | Phosphodiesterase 5A | O76074 | CHEMBL1827 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
| Protein Kinase | MAPK3 | MAP kinase ERK1 | P27361 | CHEMBL3385 |
| Protein Kinase | LCK | Tyrosine-protein kinase LCK | P06239 | CHEMBL258 |
| Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.835E-09 | 1.500E-05 | CA2, CA7, FYN, HMGCR, LCK, MAPK1, MAPK14, MAPK3, MIF |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.067E-09 | 1.500E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.771E-08 | 2.181E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.009E-07 | 3.976E-04 | CA12, CA2, CA4, CA7 |
| MF | Unclassified; | GO:0004707; MAP kinase activity | 5.322E-07 | 7.726E-04 | MAPK1, MAPK14, MAPK3 |
| MF | Unclassified; | GO:0004708; MAP kinase kinase activity | 6.647E-07 | 9.047E-04 | MAPK1, MAPK14, MAPK3 |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 1.350E-06 | 1.181E-03 | L3MBTL1, LCK, MAPK1, MAPK3, POLB |
| MF | GO:0005488; binding | GO:0042610; CD8 receptor binding | 1.356E-06 | 1.181E-03 | FYN, LCK |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.066E-06 | 2.856E-03 | CA2, CA7 |
| BP | GO:0065007; biological regulation | GO:0030641; regulation of cellular pH | 4.525E-06 | 3.041E-03 | CA2, CA7, MAPK1, MAPK3 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.944E-06 | 3.412E-03 | CA2, CA7, MAPK1, MAPK14, MAPK3 |
| BP | GO:0050896; response to stimulus | GO:0031663; lipopolysaccharide-mediated signaling pathway | 6.486E-06 | 3.445E-03 | MAPK1, MAPK14, MAPK3 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 6.486E-06 | 3.445E-03 | CYP1A2, MAPK1, MAPK3 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 8.110E-06 | 3.611E-03 | FYN, LCK, MAPK1, MAPK3 |
| BP | GO:0009987; cellular process | GO:0090170; regulation of Golgi inheritance | 8.126E-06 | 3.611E-03 | MAPK1, MAPK3 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.126E-06 | 3.611E-03 | CYP1A2, CYP2C9 |
| MF | GO:0005488; binding | GO:0001784; phosphotyrosine residue binding | 9.415E-06 | 4.100E-03 | LCK, MAPK1, MAPK3 |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 1.263E-05 | 5.260E-03 | MAPK1, MAPK14, MAPK3, MIF, PDE5A |
| BP | GO:0050896; response to stimulus | GO:0009628; response to abiotic stimulus | 1.280E-05 | 5.260E-03 | AKR1B1, CA2, FYN, HMGCR, MAPK14, MAPK3, POLB, USP2 |
| BP | GO:0051179; localization | GO:0072584; caveolin-mediated endocytosis | 1.353E-05 | 5.358E-03 | MAPK1, MAPK3 |
| BP | GO:0032501; multicellular organismal process | GO:0061308; cardiac neural crest cell development involved in heart development | 1.353E-05 | 5.358E-03 | MAPK1, MAPK3 |
| BP | GO:0032501; multicellular organismal process | GO:0060440; trachea formation | 2.028E-05 | 6.902E-03 | MAPK1, MAPK3 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.028E-05 | 6.902E-03 | CYP1A2, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.311E-05 | 7.510E-03 | FYN, LCK, MAPK3 |
| BP | GO:0002376; immune system process | GO:0002741; positive regulation of cytokine secretion involved in immune response | 2.838E-05 | 8.828E-03 | MAPK14, MAPK3 |
| MF | GO:0005488; binding | GO:0042608; T cell receptor binding | 2.838E-05 | 8.828E-03 | FYN, LCK |
| MF | GO:0005488; binding | GO:0042609; CD4 receptor binding | 2.838E-05 | 8.828E-03 | FYN, LCK |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.131E-09 | 4.008E-07 | CA12; CA2; CA4; CA7 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.078E-07 | 6.898E-06 | LCK; MAPK1; FYN; MAPK14; MAPK3 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.397E-07 | 1.023E-05 | TBXAS1; MAPK1; FYN; MAPK14; MAPK3 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 3.550E-07 | 1.136E-05 | LCK; MAPK1; FYN; MAPK14; MAPK3 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.031E-06 | 2.617E-05 | MAPK1; FYN; MAPK14; MAPK3 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.227E-06 | 2.617E-05 | SLCO1B1; CA2; SLCO1B3; HMGCR |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 9.992E-06 | 1.599E-04 | MAPK1; FYN; MAPK14; MAPK3 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 1.591E-05 | 2.263E-04 | LCK; MAPK1; FYN; MAPK3 |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 8.488E-06 | 1.552E-04 | MAPK1; FYN; MAPK3 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 4.578E-05 | 5.327E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 7.523E-05 | 6.799E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.733E-05 | 4.778E-04 | MAPK1; MAPK14; MAPK3 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 7.840E-05 | 6.799E-04 | MAPK1; MAPK14; MAPK3 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 5.539E-05 | 5.908E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 8.165E-05 | 6.799E-04 | MAPK1; FYN; MAPK3 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.057E-04 | 1.254E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.511E-04 | 1.074E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.882E-04 | 1.254E-03 | MAPK1; MAPK14; MAPK3 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 8.499E-05 | 6.799E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 2.057E-04 | 1.254E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 2.717E-04 | 1.374E-03 | MAPK1; FYN; MAPK3 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.277E-04 | 9.619E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.372E-04 | 1.320E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.646E-04 | 1.374E-03 | MAPK1; MAPK14; MAPK3 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.243E-04 | 1.305E-03 | MAPK1; MAPK14; MAPK3 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.502E-04 | 1.494E-03 | CYP2C9; GAA; TBXAS1; CYP1A2; AKR1B1; ALPI; HMGCR |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.790E-04 | 1.374E-03 | CYP2C9; MAPK1; MAPK3 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.253E-04 | 1.487E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.417E-04 | 1.494E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 4.035E-04 | 1.666E-03 | MAPK1; FYN; MAPK3 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 4.619E-04 | 1.739E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 4.619E-04 | 1.739E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 5.825E-04 | 1.912E-03 | MAPK1; FYN; MAPK3 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 5.592E-04 | 1.884E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 6.308E-04 | 2.019E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 8.956E-04 | 2.784E-03 | MAPK1; PDE5A; MAPK3 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.025E-03 | 2.983E-03 | MAPK1; MAPK14; MAPK3 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.571E-03 | 4.147E-03 | MAPK1; MAPK14; MAPK3 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.077E-03 | 3.063E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.549E-03 | 4.147E-03 | MAPK1; FYN; MAPK3 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.616E-03 | 4.147E-03 | POLB; MAPK1; MAPK3 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.754E-03 | 4.403E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 3.004E-03 | 5.826E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.150E-03 | 5.004E-03 | MAPK1; MAPK3 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.876E-03 | 4.618E-03 | MAPK1; MAPK3 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.620E-03 | 4.147E-03 | MAPK1; MAPK3 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.943E-03 | 4.692E-03 | MAPK1; MAPK3 |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 2.150E-03 | 5.004E-03 | MAPK1; MAPK3 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.518E-03 | 5.357E-03 | MAPK1; MAPK3 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.294E-03 | 5.151E-03 | MAPK1; MAPK3 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.118E-02 | 1.645E-02 | MAPK1; MAPK3 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 5.735E-03 | 9.415E-03 | MAPK1; MAPK3 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 4.460E-03 | 7.928E-03 | MAPK1; MAPK3 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 2.595E-03 | 5.357E-03 | MAPK1; MAPK3 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.382E-03 | 3.845E-03 | MAPK1; MAPK3 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.211E-02 | 1.762E-02 | MAPK1; MAPK3 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 5.079E-03 | 8.667E-03 | MAPK1; MAPK3 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.996E-03 | 5.826E-03 | MAPK1; MAPK3 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.164E-03 | 5.869E-03 | MAPK1; MAPK3 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.662E-03 | 8.064E-03 | MAPK1; MAPK3 |
| hsa04350 | TGF-beta signaling pathway_Homo sapiens_hsa04350 | 4.164E-03 | 7.508E-03 | MAPK1; MAPK3 |
| hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 5.293E-03 | 8.915E-03 | MAPK1; MAPK3 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 5.848E-03 | 9.475E-03 | MAPK1; MAPK3 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 2.595E-03 | 5.357E-03 | MAPK1; MAPK3 |
| hsa04724 | Glutamatergic synapse_Homo sapiens_hsa04724 | 7.535E-03 | 1.176E-02 | MAPK1; MAPK3 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.407E-02 | 2.024E-02 | MAPK1; MAPK3 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.103E-02 | 1.641E-02 | MAPK1; MAPK3 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.595E-03 | 5.357E-03 | MAPK1; MAPK3 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.673E-03 | 5.430E-03 | MAPK1; MAPK3 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 3.164E-03 | 5.869E-03 | MAPK1; MAPK3 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.518E-03 | 5.357E-03 | CYP2C9; CYP1A2 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 5.962E-03 | 9.539E-03 | MAPK1; MAPK3 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 1.781E-02 | 2.478E-02 | MAPK1; MAPK3 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 6.193E-03 | 9.786E-03 | MAPK1; MAPK3 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 2.487E-02 | 3.300E-02 | MAPK1; MAPK3 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.581E-02 | 2.248E-02 | MAPK1; MAPK3 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 8.723E-03 | 1.314E-02 | MAPK1; MAPK3 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 8.053E-03 | 1.242E-02 | MAPK1; MAPK3 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.009E-03 | 2.983E-03 | MAPK1; MAPK3 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 3.510E-02 | 4.493E-02 | POLB; LCK |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 2.774E-02 | 3.624E-02 | MAPK1; MAPK3 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.934E-02 | 2.639E-02 | MAPK1; MAPK3 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 4.560E-03 | 7.996E-03 | MAPK1; MAPK3 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 5.040E-04 | 1.792E-03 | MAPK1; MAPK3 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 8.318E-03 | 1.268E-02 | MAPK1; MAPK3 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.173E-02 | 2.927E-02 | MAPK1; MAPK3 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 9.135E-04 | 2.784E-03 | MAPK1; MAPK3 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 4.363E-04 | 1.739E-03 | MAPK1; MAPK3 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.973E-03 | 7.265E-03 | CYP2C9; CYP1A2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.294E-03 | 5.151E-03 | CYP2C9; TBXAS1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.832E-03 | 5.664E-03 | CYP2C9; CYP1A2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.164E-03 | 5.869E-03 | CYP2C9; CYP1A2 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.154E-04 | 1.487E-03 | CA2; CA4 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.396E-04 | 1.867E-03 | GAA; AKR1B1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.040E-04 | 1.792E-03 | CYP2C9; CYP1A2 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 3.951E-02 | 4.909E-02 | MIF |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 3.618E-02 | 4.585E-02 | AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 3.729E-02 | 4.679E-02 | POLB |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 4.061E-02 | 4.998E-02 | AKR1B1 |
| hsa04966 | Collecting duct acid secretion_Homo sapiens_hsa04966 | 3.061E-02 | 3.958E-02 | CA2 |
| hsa00900 | Terpenoid backbone biosynthesis_Homo sapiens_hsa00900 | 2.501E-02 | 3.300E-02 | HMGCR |
| hsa00360 | Phenylalanine metabolism_Homo sapiens_hsa00360 | 1.938E-02 | 2.639E-02 | MIF |
| hsa00790 | Folate biosynthesis_Homo sapiens_hsa00790 | 1.599E-02 | 2.248E-02 | ALPI |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.737E-03 | 9.415E-03 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HMGCR; PDE5A |
| NA: NA | Cardiovascular disease | NA | HMGCR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PDE5A |
| NA: NA | Rheumatold arthritis | NA | MAPK14 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MAPK14; AKR1B1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; MAPK14 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | PDE5A; TBXAS1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | PDE5A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | TBXAS1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | HMGCR |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | MAPK14; TBXAS1 |
| NA: NA | Inflammatory diseases | NA | MAPK14 |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
| NA: NA | Raynaud's disease | NA | PDE5A; PDE5A |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HMGCR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | MAPK14 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| NA: NA | Hyperlipidemia | NA | HMGCR |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | PDE5A; PDE5A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HMGCR |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HMGCR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MAPK14 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PDE5A; TBXAS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HMGCR |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF; LCK |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | HBV infection | B16, B18.0, B18.1 | HMGCR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
| NA: NA | Dyslipidemia | NA | HMGCR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | HMGCR |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Elevated CRP | E78.0 | HMGCR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | PDE5A; PDE5A |
| C00-D49: Neoplasms | Multiple myeloma | C90 | HMGCR |
| K00-K95: Diseases of the digestive system | Chemotherapy or radiotherapy-induced mucositis | K12.3, R52, G89 | HMGCR |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | HMGCR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MIF; MAPK14 |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | PDE5A; MAPK14 |
| NA: NA | Acute respiratory distress syndrome | NA | MAPK14 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | HMGCR; TBXAS1 |